{"id":30382,"date":"2013-03-01T10:34:30","date_gmt":"2013-03-01T15:04:30","guid":{"rendered":"http:\/\/piel-l.org\/blog\/?p=30382"},"modified":"2013-03-02T12:35:17","modified_gmt":"2013-03-02T17:05:17","slug":"a-novel-two-stage-treatment-of-lentigo-maligna-using-ablative-laser-therapy-followed-by-imiquimod","status":"publish","type":"post","link":"https:\/\/piel-l.org\/blog\/30382","title":{"rendered":"A Novel Two-Stage Treatment Of Lentigo Maligna Using Ablative Laser Therapy Followed By Imiquimod."},"content":{"rendered":"<p><!--more--><\/p>\n<p>Br J Dermatol. 2012 Dec 18. doi: 10.1111\/bjd.12157.<br \/>de Vries K, Rellum R, Habets JM, Prens EP.<\/p>\n<p><strong>Source<\/strong><\/p>\n<p>Erasmus Universtity Medical Center, Department of Dermatology, Rotterdam, The Netherlands DermaTeam Clinic, Middelburg, The Netherlands.<\/p>\n<p><strong>Abstract<\/strong><\/p>\n<p>Lentigo maligna (LM) is a slowly growing premalignant skin cancer, typically arising in sun-exposed skin in elderly individuals. The lifetime risk of LM progressing to LM-melanoma varies from 4.7% to 2.2%.(1) The first treatment of choice for LM, is wide local excision with a margin of at least 5 mm, which leads to clearance rates of about 24 to 70% and recurrence rates of 7 to 20%.(2) Staged surgical excision is associated with recurrence rates of 0 to 9.7%, with mean follow-up periods of 4.7 to 96 months.(2) In some patients, surgical treatment will inevitably lead to large skin defects and complex surgical reconstructions.<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":16,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8,1],"tags":[],"class_list":["post-30382","post","type-post","status-publish","format-standard","","category-articulos-cientificos","category-generales"],"_links":{"self":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/30382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/comments?post=30382"}],"version-history":[{"count":0,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/30382\/revisions"}],"wp:attachment":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media?parent=30382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/categories?post=30382"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/tags?post=30382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}